Emcure Pharmaceuticals Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Emcure Pharmaceuticals Limited Pharmaceutical Export Portfolio Dataset — 39 Products, $147.8M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Emcure Pharmaceuticals Limited — Pharmaceutical Exporter Profile (2026) | 39 Products, $147.8M Trade | TransData Nexus

Emcure Pharmaceuticals Limited

Indian Pharmaceutical Exporter · Antiviral & HIV Medications Specialist · $147.8M Total Trade · DGFT Verified

Emcure Pharmaceuticals Limited is an Indian pharmaceutical exporter with a total trade value of $147.8M across 39 products in 19 therapeutic categories. Based on 5,154 verified export shipments from Indian Customs (DGFT) records, Emcure Pharmaceuticals Limited is the #1 Indian exporter in 3 products including Melphalan, Carmustine, Diltiazem. Top exports include Dolutegravir ($19.9M), Mycophenolate ($14.4M), Tenofovir ($14.3M).

Emcure Pharmaceuticals Limited — Export Portfolio & Destination Treemap

Emcure Pharmaceuticals Limited pharmaceutical export portfolio — 39 products across 19 therapeutic categories. Source: Indian Customs (DGFT).

Who is Emcure Pharmaceuticals Limited? — Company Overview & Market Position

Emcure Pharmaceuticals Limited, established in 1981, is a leading Indian pharmaceutical company headquartered in Pune, Maharashtra. The company specializes in developing, manufacturing, and marketing a diverse range of pharmaceutical products across various therapeutic areas, including gynecology, cardiology, oncology, blood-related disorders, HIV antivirals, and more.

As of March 2026, Emcure reported a revenue of $943.7 million, reflecting an 18.6% increase from the previous year. The company employs approximately 11,474 individuals, underscoring its significant presence in the pharmaceutical industry. Emcure's product portfolio includes over 350 brands, with notable offerings such as Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym.

What Does Emcure Pharmaceuticals Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Dolutegravir$19.9M 2Mycophenolate

Product Portfolio — Top 30 by Export Value

Emcure Pharmaceuticals Limited exports 39 pharmaceutical products across 19 therapeutic categories. Market leader (#1 exporter) in 3 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Dolutegravir	Antiviral & HIV Medications	$19.9M	398	0.5%	3
2	Mycophenolate	Immunosuppressants	$14.4M	309	4.2%	5
3	Tenofovir	Antiviral & HIV Medications	$14.3M	286	0.3%	5
4	Iron	Vitamins & Supplements	$10.6M	596	2.2%	8
5	Melphalan	Advanced Oncology	$9.3M	236	69.3%	1
6	Atazanavir	Antiviral & HIV Medications	$8.3M	167	11.2%	2
7	Amlodipine	Cardiovascular	$7.0M	468	0.1%	12
8	Ritonavir	Antiviral & HIV Medications	$5.9M	118	1.6%	4
9	Amphotericin	Antifungals	$4.5M	89	5.1%	3
10	Carmustine	Advanced Oncology	$4.1M	84	18.0%	1
11	Enoxaparin	Cardiovascular	$4.1M	187	1.9%	6
12	Heparin	Cardiovascular	$3.9M	181	1.1%	10
13	Sertraline	CNS & Psychiatric	$3.5M	170	0.6%	10
14	Diltiazem	Cardiovascular	$3.2M	130	18.0%	1
15	Apixaban	Cardiovascular	$3.0M	122	1.7%	9
16	Celecoxib	Analgesics & Antipyretics	$2.3M	146	1.7%	12
17	Salbutamol	Respiratory	$2.2M	123	1.5%	6
18	Ranitidine	Gastrointestinal	$2.2M	71	17.5%	2
19	Nitrofurantoin	Advanced Antibiotics	$2.2M	67	6.3%	4
20	Bromhexine	Respiratory & OTC	$2.1M	119	13.1%	2
21	Ezetimibe	Lipid & Metabolism	$2.1M	114	0.4%	13
22	Escitalopram	CNS & Psychiatric	$2.1M	145	1.1%	15
23	Febuxostat	Lipid & Metabolism	$2.0M	52	4.1%	6
24	Dapsone	Antimalarial & Antiparasitic	$1.9M	52	8.5%	4
25	Furosemide	Diuretics	$1.8M	36	2.6%	8
26	Busulfan	Advanced Oncology	$1.5M	109	31.2%	2
27	Emtricitabine	Antiviral & HIV Medications	$1.5M	52	1.2%	10
28	Leflunomide	Immunosuppressants	$1.3M	104	7.8%	4
29	Amikacin	Advanced Antibiotics	$1.0M	20	3.8%	4
30	Acarbose	Advanced Diabetes Medications	$986.3K	24	11.4%	2

Emcure Pharmaceuticals Limited exports 39 pharmaceutical products across 19 therapeutic categories with a total export value of $147.8M. The company is the #1 Indian exporter in 3 products: Melphalan, Carmustine, Diltiazem. The top category is Antiviral & HIV Medications (33.9% of portfolio), followed by Cardiovascular (14.7%), reflecting a diversified portfolio where the top 5 products account for only 46.4% of total value.

Showing top 30 of 39 products. Contact us for complete data.

Emcure Pharmaceuticals Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Emcure operates multiple state-of-the-art manufacturing facilities across India, including a solid dosage facility in Hinjawadi, Pune, which received US FDA approval in 2006. This plant specializes in producing solid oral formulations for international regulated markets. The company's manufacturing capabilities are vertically integrated, encompassing active pharmaceutical ingredients (APIs), formulations, and biotechnology products.

3Key Leadership

The leadership team at Emcure Pharmaceuticals Limited is headed by Managing Director and Chief Executive Officer Satish Ramanlal Mehta. Other key executives include:

Samit Satish Mehta – President of Operations and Whole-Time Director
Dr. Mukund Keshao Gurjar – Chief Scientific Officer and Whole-Time Director
Sunil Rajanikant Mehta – Executive Director of Projects and Whole-Time Director
Namita Vikas Thapar – Executive Director of India Business and Whole-Time Director
Tajuddin Sabir Shaikh – Chief Financial Officer

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Emcure Pharmaceuticals Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Emcure Pharmaceuticals Limited has established a strong presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's solid dosage facility in Hinjawadi, Pune, received US FDA approval in 2006, enabling it to manufacture solid oral formulations for international regulated markets. Emcure's product portfolio includes over 350 brands, with notable offerings such as Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym.

2Emerging Markets

Emcure Pharmaceuticals Limited has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's commitment to providing affordable healthcare solutions has facilitated its penetration into these regions. Additionally, Emcure's partnership with Roche for the distribution of nephrology and transplant medicines in India demonstrates its strategic approach to enhancing healthcare access in emerging markets.

3Geographic Strategy

Emcure Pharmaceuticals Limited has adopted a diversified geographic strategy, establishing a presence in over 70 countries, including key markets in India, Europe, and Canada. This global footprint mitigates concentration risk and positions the company to leverage growth opportunities across various regions. The company's strategic direction focuses on expanding its global impact through partnerships and innovative healthcare solutions.

Emcure Pharmaceuticals Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Emcure's solid dosage facility in Hinjawadi, Pune, received US FDA approval in 2006, enabling it to manufacture solid oral formulations for international regulated markets. The facility has also been accredited by the UK MHRA, WHO Geneva, and MCC South Africa, reflecting its compliance with international quality standards.

2WHO & EU GMP

Emcure Pharmaceuticals Limited's manufacturing facility in Hinjawadi, Pune, has received accreditation from the WHO Geneva, UK MHRA, and MCC South Africa, indicating compliance with international quality standards. The company's commitment to quality is further demonstrated by its adherence to Good Manufacturing Practices (GMP) as recognized by these regulatory bodies.

3CDSCO & Indian Regulatory

Emcure Pharmaceuticals Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) in India, ensuring compliance with national regulatory standards. The company's manufacturing facility in Hinjawadi, Pune, has been approved by the CDSCO, reflecting its adherence to Indian regulatory requirements.

Emcure Pharmaceuticals Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Emcure Pharmaceuticals Limited operates in a competitive landscape with several key players in the pharmaceutical industry. The company's diversified product portfolio, including therapeutic areas such as gynecology, cardiology, oncology, and HIV antivirals, positions it favorably against competitors. Emcure's commitment to quality and innovation, as evidenced by its manufacturing facility's accreditations from the US FDA, UK MHRA, WHO Geneva, and MCC South Africa, further strengthens its competitive position.

2Key Differentiators

Emcure Pharmaceuticals Limited's key differentiators include its diversified product portfolio across major therapeutic areas, commitment to quality as demonstrated by international accreditations, and a strong presence in both domestic and international markets. The company's focus on innovation and patient-centric solutions further distinguishes it in the pharmaceutical industry.

3Strategic Position

Emcure Pharmaceuticals Limited's strategic direction focuses on expanding its global impact through partnerships and innovative healthcare solutions. The company's commitment to quality and patient-centric approaches positions it well for future growth in the pharmaceutical industry. Emcure's diversified product portfolio and global presence provide a solid foundation for its strategic initiatives.

Buyer Due Diligence Brief — Evaluating Emcure Pharmaceuticals Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Emcure Pharmaceuticals Limited has a strong track record in the pharmaceutical industry, with a diversified product portfolio and a global presence in over 70 countries. The company's manufacturing facility in Hinjawadi, Pune, has received approvals from the US FDA, UK MHRA, WHO Geneva, and MCC South Africa, indicating reliability and adherence to international quality standards.

2Certifications to Verify

Importers should verify the following certifications when considering Emcure Pharmaceuticals Limited as a supplier:

FDA Approval: Confirm the US FDA approval of Emcure's manufacturing facility in Hinjawadi, Pune, to ensure compliance with US regulatory standards.

WHO-GMP Certification: Verify the WHO-GMP certification of Emcure's manufacturing facility to ensure adherence to international quality standards.

EU GMP Certification: Ensure that Emcure's manufacturing facility holds EU GMP certification to meet European Union regulatory requirements.

Frequently Asked Questions — Emcure Pharmaceuticals Limited

How many pharmaceutical products does Emcure Pharmaceuticals Limited export from India?

Emcure Pharmaceuticals Limited exports 39 pharmaceutical products across 19 therapeutic categories. The top exports are Dolutegravir ($19.9M), Mycophenolate ($14.4M), Tenofovir ($14.3M), Iron ($10.6M), Melphalan ($9.3M). Total export value is $147.8M.

What is Emcure Pharmaceuticals Limited's total pharmaceutical export value?

Emcure Pharmaceuticals Limited's total pharmaceutical export value is $147.8M, based on 5,154 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Emcure Pharmaceuticals Limited the #1 Indian exporter?

Emcure Pharmaceuticals Limited is the #1 Indian exporter in 3 products: Melphalan (69.3% market share), Carmustine (18.0% market share), Diltiazem (18.0% market share).

What therapeutic categories does Emcure Pharmaceuticals Limited cover?

Emcure Pharmaceuticals Limited exports across 19 therapeutic categories. The largest are Antiviral & HIV Medications (33.9%, 6 products), Cardiovascular (14.7%, 6 products), Immunosuppressants (10.8%, 3 products).

Get Full Emcure Pharmaceuticals Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.